Abstracts

HAV AND HBV VACCINATION COVERAGE AND ACCEPTABILITY AMONG MSM ON PrEP

Sexually transmitted viral hepatitis have a rising incidence in MSM. During the ANRS IPERGAY PrEP trial (NCT 01473472), vaccination against HAV and HBV was offered free of charge to non-immune participants. We assessed baseline immune status, vaccine acceptability and efficacy in IPERGAY participants. All subjects included in the IPERGAY blind and/or open phases were studied.…

DISCOVER: NO EFFECT OF HORMONES ON F/TAF OR F/TDF PK, EFFICACY & SAFETY IN TRANSWOMEN

Emtricitabine (F), tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) do not have relevant drug interactions with low-dose hormones used for contraception. The current analysis explored PK as well as efficacy and safety of transwomen receiving either F/TAF or F/TDF in the DISCOVER trial, the majority of whom were taking high-dose, gender-affirming, hormonal therapy. Overall,…

TRANSPrEP: SOCIAL NETWORK–BASED PrEP ADHERENCE FOR TRANSGENDER WOMEN IN LIMA, PERU

While pre-exposure prophylaxis (PrEP) is an effective HIV prevention method, uptake remains poor among transgender women (TW). We conducted a pilot randomized controlled trial of a social network-based intervention to promote PrEP adherence among Peruvian TW. From September, 2017-July, 2018, we screened 172 TW from three geographic areas of Lima, Peru. Screening visits were conducted…